Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cellectar Biosc (CLRB)

Cellectar Biosc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cellectar Biosc 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 USA

www.cellectar.com Employees: 20 P: 608-441-8120 F: 608-441-8121

Description:

Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.

Key Statistics

Overview:

Market Capitalization, $K 75,455
Enterprise Value, $K 71,955
Shares Outstanding, K 40,567
Annual Sales, $ 0 K
Annual Net Income, $ -37,980 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -920 K
EBIT, $ -47,660 K
EBITDA, $ -47,470 K
60-Month Beta 1.00
% of Insider Shareholders 3.70%
% of Institutional Shareholders 16.41%
Float, K 39,066
% Float 96.30%
Short Volume Ratio 0.45

Growth:

1-Year Return -14.90%
3-Year Return -75.36%
5-Year Return -88.08%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 93.24%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.51 on 10/29/24
Next Earnings Date 11/18/24 [BMO]
Earnings Per Share ttm -2.39
EPS Growth vs. Prev Qtr -27.50%
EPS Growth vs. Prev Year 30.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 07/22/22

CLRB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -176.62%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 15.88
Book Value/Share 0.35
Interest Coverage -2.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar